Committee to Identify Neuroprotective Agents for Parkinson's (CINAPS) Drug Optimization Program
Funding Contact(s): Helene Braun
Funding Categories: Neurodegeneration
Brief Description:
The National Institute of Neurological Disorders and Stroke (NINDS) has a requirement to accelerate neuroprotective therapeutics
development for Parkinson's Disease (PD). PD is the second most commonly occurring neurodegenerative disease, hallmarked by
the gradual loss of dopaminergic and other neurons, as well as the accumulation of insoluble aggregates. Therefore, a primary
goal is to find rational treatments which can prevent progression of the disease once diagnosed or prevent neurons from dying
in individuals at risk for developing the disease.